In a patient with chronic kidney disease (serum creatinine ≈2 mg/dL) and elevated triglycerides who is already on bempedoic acid and ezetimibe, what lipid‑lowering regimen should be used?

Add a Statin to the Current Regimen

In a patient with CKD (creatinine ~2 mg/dL, suggesting eGFR 30-45 mL/min or CKD stage 3b) and elevated triglycerides already on bempedoic acid and ezetimibe, you should add a moderate-intensity statin. This patient is not receiving the cornerstone of lipid-lowering therapy for cardiovascular risk reduction in CKD.

Why Statins Are Essential in CKD

The 2018 AHA/ACC guidelines 1 and KDIGO 2014 guidelines 2 unequivocally recommend statins as first-line therapy for adults ≥50 years with CKD not on dialysis. CKD itself is a risk-enhancing factor that elevates 10-year ASCVD risk to ≥7.5%, making statin therapy a Class IIa recommendation 1. The SHARP trial demonstrated that statin plus ezetimibe reduces major atherosclerotic events in CKD patients 3, and this benefit persists across all stages of non-dialysis CKD 1.

The critical oversight here: Bempedoic acid and ezetimibe are add-on therapies, not replacements for statins. Current guidelines position statins as the foundation, with ezetimibe added when LDL-C goals aren't met on maximally tolerated statin therapy 4, 5.

Statin Selection in CKD Stage 3b

With a creatinine of ~2 mg/dL (eGFR likely 30-45 mL/min):

• Atorvastatin is the preferred choice: requires no dose adjustment in CKD 3 and is hepatically cleared
• Fluvastatin is an alternative: also requires no dose adjustment 3
• Avoid or use cautiously: Rosuvastatin (reduce to 5 mg daily max if eGFR <30), pravastatin, simvastatin, and lovastatin all require dose adjustments 3, 6, 3

Start with atorvastatin 20-40 mg daily (moderate-intensity) given the CKD context and existing ezetimibe therapy 7, 3.

Addressing the Elevated Triglycerides

The elevated triglycerides warrant attention, but LDL-C remains the primary target 3. After optimizing statin therapy:

For Triglycerides 135-499 mg/dL:

• Icosapent ethyl (purified EPA) is recommended if triglycerides remain elevated despite statin therapy, based on the REDUCE-IT trial 4
• This is a Class IIa recommendation in high-risk patients with hypertriglyceridemia on statins 4

For Severe Hypertriglyceridemia (≥500 mg/dL):

• Consider fibrate therapy (Class IIa) 4, but with extreme caution in CKD
• Fenofibrate requires dose adjustment: initiate at 54 mg daily and assess kidney function closely when eGFR <50 mL/min 6
• Gemfibrozil should be avoided or dose-reduced if creatinine >2 mg/dL 6 due to increased rhabdomyolysis risk when combined with statins

Therapeutic Lifestyle Changes:

• Strongly recommended for hypertriglyceridemia in CKD 2, though evidence for outcomes is weak

Practical Treatment Algorithm

1. Immediately add atorvastatin 20-40 mg daily to the existing bempedoic acid and ezetimibe
2. Continue ezetimibe (no dose adjustment needed in CKD 3, 8)
3. Continue bempedoic acid (approved for statin-intolerant patients or as add-on therapy 5)
4. Recheck lipid panel in 4-12 weeks 1
5. If triglycerides remain 135-499 mg/dL on statin therapy: add icosapent ethyl
6. If triglycerides ≥500 mg/dL: consider fenofibrate 54 mg daily with close monitoring of kidney function and muscle symptoms

Critical Monitoring Considerations

• Watch for myopathy: The combination of statin + ezetimibe + bempedoic acid increases theoretical risk, though bempedoic acid doesn't cause muscle-related adverse events 5
• Avoid gemfibrozil if adding a fibrate: it significantly increases statin levels and rhabdomyolysis risk 6, 9
• Monitor kidney function: Statins don't worsen CKD progression 3, but fenofibrate requires careful dose adjustment 6
• If patient progresses to dialysis (stage 5 CKD): continue the statin but don't initiate new lipid-lowering therapy 1, 2

Common Pitfall to Avoid

Do not assume bempedoic acid replaces statin therapy. Bempedoic acid is FDA-approved for patients who are statin-intolerant or need additional LDL-C lowering 5, 10. The 2024 ESC guidelines position it as add-on therapy after statins and ezetimibe 5. Without a documented statin intolerance or contraindication, this patient should be on a statin as the foundation of therapy.

The evidence is clear: statins reduce cardiovascular events and mortality in CKD stages 1-4 1, 3, 2, and their absence represents a significant gap in this patient's cardiovascular risk reduction strategy.